

AUSTRALIAN

RESEARCH



Contents

This is an extract from the February 2006 Health and Life Science Review

IMPORTANT NOTICE

Aegis has been commissioned to produce this report.

Disclaimer & Disclosure of Interests

This publication has been prepared by Aegis Equities Research Pty Limited (ACN 085 293 910, AFSL no. 225072) ('Aegis'), an Australian Financial Services Licensee. Aegis has been commissioned to prepare this independent research report (the "Report") and will receive fees for its preparation. Each company specified in the Report (the "Participants") has provided Aegis with information about its activities. Whilst the information contained in this publication has been prepared with all reasonable care from sources that Aegis believes are reliable, no responsibility or liability is accepted by Aegis for any errors, omissions or misstatements however caused. Any opinions, forecasts or recommendations reflects the judgment and assumptions of Aegis as at the date of publication and may change without notice. Aegis and each Participant in the Report, their officers, agents and employees exclude all liability whatsoever, in negligence or otherwise, for any loss or damage relating to this document to the full extent permitted by law. This publication is not and should not be construed as, an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Any opinion contained in the Report is unsolicited general information only. Neither Aegis nor the Participants are aware that any recipient intends to rely on this Report or of the manner in which a recipient intends to use it. In preparing our information, it is not possible to take into consideration the investment objectives, financial situation or particular needs of any individual recipient. Investors should obtain individual financial advice from their investment advisor to determine whether opinions or recommendations (if any) contained in this publication are appropriate to their investment objectives, financial situation or particular needs before acting on such opinions or recommendations. This publication is not for public circulation or reproduction whether in whole or in part and is not to be disclosed to any person other than the intended recipient, without obtaining the prior written consent of Aegis. Aegis and/or each Participant, their officers, employees or its related bodies corporate may, from time to time hold positions in any securities included in this Report and may buy or sell such securities or engage in other transactions involving such securities. Aegis and the Participants, their directors and associates declare that from time to time they may hold interests in and/or earn brokerage, fees or other benefits from the securities mentioned in this publication.

Aegis, its officers, employees and its related bodies corporate have not and will not receive, whether directly or indirectly, any commission, fee, benefit or advantage, whether pecuniary or otherwise in connection with making any statements and/or recommendation (if any), contained in this Report. Aegis discloses that from time to time it or its officers, employees and related bodies corporate may have an interest in the securities, directly or indirectly, which are the subject of these statements and/or recommendations (if any) and may buy or sell securities in the companies mentioned in this publication; may effect transactions which may not be consistent with the statements and/or recommendations (if any) in this publication; may have directorships in the companies mentioned in this publication; and/or may perform paid services for the companies that are the subject of such statements and/or recommendations (if any).

However, under no circumstances has Aegis been influenced, either directly or indirectly, in making any statements and/or recommendations (if any) contained in this Report.

The information contained in this publication must be read in conjunction with the Legal Notice that can be located at <http://www.aer.com.au/disclaimer.asp>.

Imugene Limited (IMU)



Sector	Industry Group	Sub Industry	Disease Target
Life Sciences	Biotechnology	Animal Health Products	infectious diseases of Poultry & Pigs

Company Overview

Imugene is an animal health biopharmaceutical company developing and commercialising biological products for the intensively farmed pig and poultry industries.

Imugene's products have advantages over existing products including:

- (i) substantially improving the health of animals;
- (ii) improving productivity and profitability for poultry and pig producers; and
- (iii) reducing consumer exposure to antibiotic, hormone and chemical residues by using safe biodegradable, biological treatments, thereby reducing development of antibiotic resistant 'superbugs'.

Detailed information on Imugene, its products and strategy is contained on the company's website: www.imugene.com.

Strategy

Global commercialisation of Imugene's biological products through sublicense agreements with the top global animal health companies.

The 'Poultry Productivity Enhancer', Imugene's most advanced product, has recently been sublicensed to Merial, one of the world's largest animal health companies (annual sales of US\$1.8 billion and employs 5,000 people).

Merial will now drive the regulatory, development, marketing and distribution of the product worldwide using their vast resources.

A further contract was recently signed with Teva Pharmaceuticals to develop a vaccine against coccidiosis in poultry. Cocci is one of the most common and costly diseases in poultry.

Imugene will receive license fees and royalty income on product sales without further expenditure on the product, thereby maximising profits and shareholder returns.

Key Executives

Graham Dowland (BComm, ACA), Executive Chairman: Has over 15 years' experience as executive director in assisting public companies listed in Australia, Canada and the UK particularly during development phases.

Dr Warwick Lamb (BVSc, M Vet Clin Stud, FACVSc), Managing Director: A specialist veterinarian with 15 years' experience, including R & D contract projects with major international veterinary pharmaceutical companies.

Dr Michael Sheppard (BSc(Hons), PhD), Chief Scientific Officer: A molecular biologist (who with Dr. Kevin Fahey) was a key initiator of production animal compounds at CSIRO. Has gained international commercial experience in the US with the world's largest pharmaceutical company, Pfizer.

Dr Kevin Fahey (BSc, MSc, PhD, FASM), Chairman – Commercialisation R & D; Scientific Advisory Board: Has had a distinguished international corporate and scientific career, most previously as Scientific Director – Research Investments for Pfizer Global R & D (USA).

Key investment information

Market Cap: \$25.5M

Capital Structure (M)

Ord shares on issue: 130.6

Options (fully diluted): 16.6

Convertible notes/other: 0.0

Price as at 30-Jan: \$0.20

12 month H/L: \$0.11 - \$0.28

Market turnover (pa): \$17.5M

Official listing date: Oct 02

Substantial Shareholders

Queensland Investment Corp 6.4%

Graham Dowland 5.2%

Cash Position

Cash (as at Dec-05): \$3.4M

Years with planned expenditure: 2

R&D as % expenditure: 70%

Company contact



Dr Warwick Lamb
Managing Director

wlamb@imugene.com
61 2 9870 7330

www.imugene.com

Main Company R&D Projects - Major Technology & Market

1: Poultry Productivity Enhancer

Target Market: Global poultry market
>US\$1B
Stage: Merial sub-licensed for
global market
Target Date: 2006-2007

There is a growing need globally to improve the productivity of meat animals globally - without using chemical growth promotants (antibiotics). The Imugene product increases chicken growth by 15%, using significantly less feed and is applicable to all poultry farms. The product is non chemical, is inexpensive to manufacture, safe for animals and humans and has the big advantage of administration to large numbers of birds quickly and cheaply.

2: Bird Flu

Target Market: Global Poultry Market
>US\$500M
Stage: Proof of Concept
Target Date: 2006/7

Developing an effective vaccine against the current Bird Flu is a priority for Imugene. The vaccine under development has major advantages - safety and ability to be used on a mass scale as the vaccine can be delivered through water or feed. Trials are underway to determine the dosage to achieve the most effective antibody response.

3: Imugene Pipeline

Target Market: Vaccines and other products
for global production animal
markets >US\$1.5B
Stage: Proof of Principle to
commercial contracts
Target Date: 2006-2008

Imugene is developing a number of other vaccines for poultry and pigs. The lead pig product PRRS addresses a disease affecting 80% of pig herds worldwide, has no competitors and could be alone in a US\$400Mpa market. A research contract was recently signed with Teva Pharmaceuticals to develop a vaccine against coccidiosis in poultry.

4: Pig Diarrhoea Treatment

Target Market: US\$450M
Stage: scale up and efficacy trials
Target Date: 2007/8

The Receptor Mimic Technology (RMT) product binds and neutralises disease-causing toxins. Bacterial toxins are the major cause of diarrhoea and loss in weaning piglets. This has been treated to date, with mixed results, by antibiotics. Antibiotics are being banned. Biological products (like RMT) have a much faster path to market than drugs.

Aegis Equities Comments

Market Position: IMU made a quantum leap forward in the Dec-05 quarter by executing deals with two global pharmas. Merial, one of the world's largest animal health companies, licensed IMU's Poultry Productivity Enhancer (PPE). Teva's animal health unit, Abic, will develop a vaccine against poultry coccidiosis using IMU's patented Adenoviral Vector Technology. A successful vaccine will lead to a license deal. IMU's patented Receptor Mimic Technology is initially targeting Post-Weaning Diarrhoea in pigs. IMU's products are residue-free, non-antibiotic and chemical-free, in line with worldwide consumer demand for higher quality food and increasing regulatory bans on antibiotic use.


Milestone Record: The Abic/Teva deal was signed in Dec-05, while the Merial deal was done in Oct-05. Teva is a global top 20 pharma. Merial is an ideal partner, having global sales of US\$1.7B, an experienced sales and marketing team, worldwide distribution and market leading status. Both Abic and Merial will pay IMU royalties on future product sales. IMU's PRRS vaccine is being evaluated by major animal health companies. IMU is progressing a Bird Flu vaccine.

Risk Profile: Merial's milestone payments, due when the PPE meets development targets, mitigate financial risk. Animal health products typically take less than half the time to bring to market than human drugs, lowering development risk. IMU's biological products do not need toxicity tests, making them even easier and quicker to approve. IMU had \$3.4M cash at Dec-05, projected to last two years.

Commercial poultry shed



Share price performance



Source: Bloomberg



Level 6, 33 York Street
Sydney NSW 2000 Australia
Locked Bag 7 Australia Square
Sydney NSW 1215
Phone 61 2 8296 1100
Fax 61 2 9299 3777
ABN 72 085 293 910
www.aer.com.au